FDA granted accelerated approval to Alecensa (alectinib) for the treatment of people with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer, who have progressed on or are intolerant to crizotinib.
A curious piece of paper hangs in a frame outside the director’s office at University of Iowa Holden Comprehensive Cancer Center on the second floor of the General Hospital.
